Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

A combined therapy with the strongly antiresorptive Alendronate and the pleiotropically acting D-hormone analogue Alfacalcidol may have additive effects on bone quality, falls and fracture risk in established osteoporosis.

Analysis was intention-to-treat and the primary outcome was lumbar spine and total hip bone mineral density (measured observer blind).

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized and parallel-group study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

BMD was measured at the lumbar spine and at the proximal femur with dual energy X-ray absorptiometry (LUNAR Prodigy, GE, USA) at the beginning and after 12 and 24 months.

What Was Measured

Analysis was intention-to-treat and the primary outcome was lumbar spine and total hip bone mineral density (measured observer blind).

Topics PubMed links to this paper include Alendronate, Bone Density, Bone Density Conservation Agents, Hydroxycholecalciferols, Osteoporosis, Postmenopausal, Spinal Fractures and Vitamin D.

What This Means in Plain Language

The paper is a randomized and parallel-group study of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2007 (Rheumatology international), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.